MCID: LYM012
MIFTS: 47

Lymphoplasmacytic Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Lymphoplasmacytic Lymphoma

MalaCards integrated aliases for Lymphoplasmacytic Lymphoma:

Name: Lymphoplasmacytic Lymphoma 12 36 15 37
Malignant Lymphoma - Lymphoplasmacytic 71
Waldenstrom Macroglobulinemia 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0050747
KEGG 36 H00011
UMLS 71 C0024419 C0334633

Summaries for Lymphoplasmacytic Lymphoma

KEGG : 36 Lymphoplasmacytic lymphoma (LPL)/Waldenstrom's macroglobulinemia (WM) is a non-Hodgkin lymphoma (NHL) subtype characterized by small B-lymphocytes, plasmacytoid lymphocytes, and plasma cells, usually involving bone marrow, lymph nodes, and the spleen. WM can be distinguished clinically from LPL on the basis of a detectable monoclonal (IgM) immunoglobulin spike in serum. In the general population, LPL/WM is a very rare disease, accounting for only 1%-2% of all hematologic malignancies, reflected in an incidence rate of 3-4 cases per million people per year. The t(9;14)(p13;q32) is present in near 50% of cases of LPL. This chromosomal translocation involves a junction between 9p13 and the switch micro region of the Ig heavy chain locus on 14q32. The 9p13 breakpoint contains the PAX-5 gene which encodes a B-cell specific transcription factor involved in the control of B-cell proliferation and differentiation. The translocation causes the juxtaposition of the PAX-5 gene to the IgH locus in the opposite direction of transcription, resulting in an 11-fold over-expression of PAX-5 mRNA.

MalaCards based summary : Lymphoplasmacytic Lymphoma, also known as malignant lymphoma - lymphoplasmacytic, is related to waldenstroem's macroglobulinemia and macroglobulinemia. An important gene associated with Lymphoplasmacytic Lymphoma is MIR155 (MicroRNA 155), and among its related pathways/superpathways are Transcriptional misregulation in cancer and MicroRNAs in cancer. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A B-cell lymphocytic neoplasm characterized by an uncontrolled increase of B-cells.

Wikipedia : 74 Waldenström macroglobulinemia (WM), is a type of cancer affecting two types of B cells:... more...

Related Diseases for Lymphoplasmacytic Lymphoma

Diseases related to Lymphoplasmacytic Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 187, show less)
# Related Disease Score Top Affiliating Genes
1 waldenstroem's macroglobulinemia 33.9 MYD88 MAG CXCR4 CD40LG
2 macroglobulinemia 31.6 PAX5 MYD88 CXCR4 CXCL12 CD40LG
3 gamma heavy chain disease 30.8 MYD88 CD40LG
4 heavy chain disease 30.8 MYD88 CD40LG
5 lymphoma 30.8 PAX5 MYD88 MS4A1 IRF4 CXCR4 CD40LG
6 marginal zone b-cell lymphoma 30.7 PAX5 MYD88 IRF4 CD40LG CCND1
7 bone lymphoma 30.6 PAX5 IRF4
8 lymphoma, hodgkin, classic 30.5 PAX5 MS4A1 MIR155 IRF4
9 cll/sll 30.4 ZAP70 PAX5 CCND1
10 diffuse large b-cell lymphoma 30.3 PAX5 MYD88 MIR155 IRF4 CXCR4 CCND1
11 plasmacytoma 30.1 PAX5 IRF4 IGH CXCL12 CCND1
12 plasma cell neoplasm 30.1 PAX5 IRF4 CD40LG CCND1
13 myeloma, multiple 29.9 PAX5 IRF4 CXCR4 CXCL12 CD40LG CCND1
14 monoclonal gammopathy of uncertain significance 29.8 MYD88 MAG IRF4 CD40LG CCND1
15 follicular lymphoma 29.8 PAX5 MS4A1 MIR155 IRF4 IGH CCND1
16 mature b-cell neoplasm 29.7 PAX5 MIR155 IRF4 CD40LG CCND1
17 b-cell lymphoma 29.6 ZAP70 PAX5 MYD88 MS4A1 MIR155 IRF4
18 burkitt lymphoma 29.5 PAX5 MS4A1 MIR155 IRF4 CD40LG CCND1
19 lymphoma, mucosa-associated lymphoid type 29.4 ZAP70 PAX5 MYD88 IRF4 IGH CD40LG
20 mantle cell lymphoma 29.3 PAX5 MS4A1 MIR155 IGH CXCR4 CD40LG
21 lymphoma, non-hodgkin, familial 29.2 PAX5 MYD88 MS4A1 MIR155 IRF4 IGH
22 leukemia, acute lymphoblastic 29.0 ZAP70 PAX5 MIR155 IRF4 IGH CXCR4
23 leukemia, chronic lymphocytic 28.5 ZAP70 PAX5 MYD88 MS4A1 MIR542 MIR155
24 lymphoplasmacytic lymphoma without igm production 12.4
25 monoclonal paraproteinemia 10.5 PAX5 CD40LG
26 aids dementia complex 10.5 CXCR4 CXCL12
27 intraocular lymphoma 10.4 PAX5 CXCR4 CXCL12
28 plasma protein metabolism disease 10.4 MYD88 CXCR4 CD40LG
29 osteosclerotic myeloma 10.4 MAG CD40LG
30 mental retardation, autosomal dominant 40 10.4 CXCR4 CXCL12
31 chronic polyneuropathy 10.4 MAG CD40LG
32 nodular lymphocyte predominant hodgkin lymphoma 10.4 PAX5 CCND1
33 agammaglobulinemia, x-linked 10.4 CXCR4 CXCL12 CD40LG
34 whim syndrome 10.4 CXCR4 CXCL12 ACKR3
35 asymmetric motor neuropathy 10.4 MAG CD40LG
36 primary cutaneous diffuse large b-cell lymphoma, leg type 10.4 MYD88 IRF4
37 primary central nervous system lymphoma 10.4 PAX5 MYD88
38 cerebral lymphoma 10.4 MAG CD40LG
39 spastic monoplegia 10.4 HAS1 CD40LG
40 autoimmune peripheral neuropathy 10.3 MAG CD40LG
41 breast lymphoma 10.3 PAX5 IRF4
42 tracheal lymphoma 10.3 PAX5 CCND1
43 splenomegaly 10.3
44 central nervous system lymphoma 10.3 PAX5 MYD88 CXCR4 CXCL12
45 mononeuritis of upper limb and mononeuritis multiplex 10.3 MAG CD40LG
46 polyradiculoneuropathy 10.3 MAG CXCR4 CXCL12
47 primary cutaneous b-cell lymphoma 10.3 PAX5 MS4A1
48 primary bacterial infectious disease 10.3 MYD88 MIR155 CD40LG
49 alpha chain disease 10.3 CD40LG CCND1
50 mononeuritis multiplex 10.3 MAG CD40LG
51 central nervous system hematologic cancer 10.3 PAX5 MYD88 IRF4
52 multicentric castleman disease 10.3 PAX5 IRF4 IGH
53 histiocytosis 10.2
54 b cell prolymphocytic leukemia 10.2 ZAP70 MS4A1
55 spleen cancer 10.2 PAX5 MYD88 CD40LG CCND1
56 lymphoproliferative syndrome 10.2
57 pancytopenia 10.2
58 amyloidosis 10.2
59 leukemia, chronic lymphocytic 2 10.2 ZAP70 MS4A1
60 polymorphous low-grade adenocarcinoma 10.2 MYH11 CCND1
61 graft-versus-host disease 10.1
62 thrombocytopenia 10.1
63 hepatitis c 10.1
64 cryoglobulinemia 10.1
65 chromosomal triplication 10.1
66 cold agglutinin disease 10.1
67 autoimmune disease of central nervous system 10.1 MIR155 MAG CD40LG
68 peripheral t-cell lymphoma 10.1 PAX5 MS4A1 CXCR4 CCND1
69 autoimmune neuropathy 10.1 MAG CD40LG
70 anemia, autoimmune hemolytic 10.0
71 aplastic anemia 10.0
72 hepatitis c virus 10.0
73 myelodysplastic syndrome 10.0
74 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.0
75 splenic marginal zone lymphoma 10.0
76 nodal marginal zone lymphoma 10.0
77 acquired von willebrand syndrome 10.0
78 respiratory failure 10.0
79 nephrotic syndrome 10.0
80 diarrhea 10.0
81 polyneuropathy 10.0
82 richter's syndrome 10.0
83 agammaglobulinemia 10.0
84 hemolytic anemia 10.0
85 thyroiditis 10.0
86 herpes zoster 10.0
87 myeloid leukemia 10.0
88 al amyloidosis 10.0
89 indolent b cell lymphoma 10.0
90 headache 10.0
91 lymphatic system cancer 10.0 MIR155 IRF4 CD40LG CCND1
92 lymphatic system disease 9.9 MIR155 IRF4 CD40LG CCND1
93 extramedullary plasmacytoma 9.9 IRF4 CCND1
94 cardiac arrhythmia 9.9
95 cryoglobulinemia, familial mixed 9.9
96 hashimoto thyroiditis 9.9
97 prostate cancer 9.9
98 scleroderma, familial progressive 9.9
99 temporal arteritis 9.9
100 thrombophilia due to thrombin defect 9.9
101 gaucher disease, type i 9.9
102 polycythemia vera 9.9
103 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 9.9
104 wiskott-aldrich syndrome 9.9
105 retinitis pigmentosa 11 9.9
106 yemenite deaf-blind hypopigmentation syndrome 9.9
107 allergic rhinitis 9.9
108 leukemia, chronic myeloid 9.9
109 deficiency anemia 9.9
110 ptosis 9.9
111 paroxysmal nocturnal hemoglobinuria 9.9
112 pollen allergy 9.9
113 thrombosis 9.9
114 castleman disease 9.9
115 prostate lymphoma 9.9
116 gastric lymphoma 9.9
117 disseminated intravascular coagulation 9.9
118 pyelonephritis 9.9
119 hemosiderosis 9.9
120 goiter 9.9
121 neutropenia 9.9
122 von willebrand's disease 9.9
123 guillain-barre syndrome 9.9
124 acute cystitis 9.9
125 toxic shock syndrome 9.9
126 renal tubular acidosis 9.9
127 prostatitis 9.9
128 nodular nonsuppurative panniculitis 9.9
129 gaucher's disease 9.9
130 pharyngitis 9.9
131 nocardiosis 9.9
132 membranoproliferative glomerulonephritis 9.9
133 glomerulonephritis 9.9
134 iga glomerulonephritis 9.9
135 acute kidney failure 9.9
136 gingivitis 9.9
137 liposarcoma 9.9
138 skin carcinoma 9.9
139 mastocytosis 9.9
140 lactic acidosis 9.9
141 myopathy 9.9
142 hepatitis e 9.9
143 kidney disease 9.9
144 peripheral nervous system disease 9.9
145 hemoglobinuria 9.9
146 composite lymphoma 9.9
147 bronchitis 9.9
148 hypersplenism 9.9
149 periodontitis 9.9
150 polycythemia 9.9
151 collagen disease 9.9
152 hodgkin's lymphoma, lymphocytic-histiocytic predominance 9.9
153 vasculitis 9.9
154 neuropathy 9.9
155 neurofibromatosis 9.9
156 evans' syndrome 9.9
157 gastrointestinal lymphoma 9.9
158 peliosis hepatis 9.9
159 exophthalmos 9.9
160 plasma cell leukemia 9.9
161 smoldering myeloma 9.9
162 polyarteritis nodosa 9.9
163 hypereosinophilic syndrome 9.9
164 hypoglycemia 9.9
165 47,xyy 9.9
166 acute graft versus host disease 9.9
167 distal renal tubular acidosis 9.9
168 immunotactoid glomerulopathy 9.9
169 necrobiotic xanthogranuloma 9.9
170 b-cell non-hodgkin lymphoma 9.9
171 acute sensory ataxic neuropathy 9.9
172 primary bone lymphoma 9.9
173 indolent b-cell non-hodgkin lymphoma 9.9
174 ah amyloidosis 9.9
175 cancer-associated retinopathy 9.9
176 intravascular large b-cell lymphoma 9.9
177 bone marrow cancer 9.9 IRF4 CD40LG CCND1
178 leukocyte disease 9.9 MIR155 IRF4 CXCR4 CD40LG CCND1
179 testicular lymphoma 9.8 MYD88 IRF4
180 combined t cell and b cell immunodeficiency 9.8 ZAP70 IRF4 CXCR4 CXCL12 CD40LG
181 immune deficiency disease 9.8 ZAP70 IRF4 CXCR4 CXCL12 CD40LG
182 common variable immunodeficiency 9.8 ZAP70 MS4A1 IRF4 CD40LG
183 squamous cell carcinoma, head and neck 9.7 MIR542 MIR494 MIR155 CXCR4 CXCL12 CCND1
184 severe combined immunodeficiency 9.7 ZAP70 IRF4 CXCR4 CXCL12
185 leukemia, acute myeloid 9.5 PAX5 MYH11 MIR542 MIR184 MIR155 CXCR4
186 systemic lupus erythematosus 9.5 MYD88 MIR494 MIR184 MIR155 IRF4 CXCR4
187 hematologic cancer 9.1 ZAP70 PAX5 MIR542 MIR155 IRF4 CXCR4

Graphical network of the top 20 diseases related to Lymphoplasmacytic Lymphoma:



Diseases related to Lymphoplasmacytic Lymphoma

Symptoms & Phenotypes for Lymphoplasmacytic Lymphoma

MGI Mouse Phenotypes related to Lymphoplasmacytic Lymphoma:

45 (showing 2, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 ACKR3 CCND1 CD40LG CXCL12 CXCR4 IRF4
2 immune system MP:0005387 9.36 ACKR3 CCND1 CD40LG CXCL12 CXCR4 IRF4

Drugs & Therapeutics for Lymphoplasmacytic Lymphoma

Drugs for Lymphoplasmacytic Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 275, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
2
Lenograstim Approved, Investigational Phase 4 135968-09-1
3
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
4 Alkylating Agents Phase 4
5
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
6
Chlorambucil Approved Phase 3 305-03-3 2708
7
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
8
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
9
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
10
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
11
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
12
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
13
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
14
Morphine Approved, Investigational Phase 3 57-27-2 5288826
15
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
16
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
17
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
18
Tazobactam Approved Phase 3 89786-04-9 123630
19
Vancomycin Approved Phase 3 1404-90-6 14969 441141
20
Piperacillin Approved Phase 3 66258-76-2 43672
21
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
22
Zanubrutinib Approved, Investigational Phase 3 1691249-45-2
23
Idelalisib Approved Phase 3 870281-82-6
24 Anesthetics Phase 3
25 Anesthetics, General Phase 3
26 Anesthetics, Intravenous Phase 3
27 Anesthetics, Dissociative Phase 3
28 Anti-Bacterial Agents Phase 3
29 Antifungal Agents Phase 3
30 Neurotransmitter Agents Phase 3
31 Etoposide phosphate Phase 2, Phase 3
32 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
33 Antiparasitic Agents Phase 3
34 Antiprotozoal Agents Phase 3
35 Analgesics Phase 3
36 Hematinics Phase 3
37 Analgesics, Opioid Phase 3
38 Excitatory Amino Acid Antagonists Phase 3
39 Respiratory System Agents Phase 3
40 Antitussive Agents Phase 3
41 Narcotics Phase 3
42 Epoetin alfa Phase 3 113427-24-0
43 Piperacillin, Tazobactam Drug Combination Phase 3
44 ferric gluconate Phase 3
45 Iron Supplement Phase 3
46 Amebicides Phase 3
47 Liposomal amphotericin B Phase 3
48
protease inhibitors Phase 3
49 HIV Protease Inhibitors Phase 3
50 BB 1101 Phase 3
51 Bendamustine Hydrochloride Phase 3
52
belimumab Approved Phase 2 356547-88-1 10451420 5957
53
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
54
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
55
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 439693 40926
56
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
57
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
58
Mesna Approved, Investigational Phase 1, Phase 2 3375-50-6 598
59
Mitoxantrone Approved, Investigational Phase 1, Phase 2 65271-80-9 4212
60
Iodine Approved, Investigational Phase 2 7553-56-2 807
61
Erythromycin Approved, Investigational, Vet_approved Phase 2 114-07-8 12560 441411
62
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
63
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
64
Gemcitabine Approved Phase 2 95058-81-4 60750
65
Methylcobalamin Approved, Investigational Phase 1, Phase 2 13422-55-4
66
Hydroxocobalamin Approved Phase 1, Phase 2 13422-51-0 15589840 11953898
67
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
68
Denileukin diftitox Approved, Investigational Phase 2 173146-27-5
69
Cobalt Approved, Experimental Phase 2 7440-48-4 104729
70
Atorvastatin Approved Phase 2 134523-00-5 60823
71
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
72
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
73
Bleomycin Approved, Investigational Phase 2 11056-06-7 5360373
74
Mannitol Approved, Investigational Phase 2 69-65-8 6251 453
75
Benzyl alcohol Approved Phase 2 100-51-6 244
76
nivolumab Approved Phase 1, Phase 2 946414-94-4
77
Triamcinolone Approved, Vet_approved Phase 2 124-94-7 31307
78
Vidarabine Approved, Investigational Phase 1, Phase 2 24356-66-9 21704 32326
79
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
80
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
81
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
82 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
83
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
84
Promethazine Approved, Investigational Phase 2 60-87-7 4927
85
Acetaminophen Approved Phase 2 103-90-2 1983
86
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
87
Obinutuzumab Approved, Investigational Phase 2 949142-50-1
88
Sodium citrate Approved, Investigational Phase 2 68-04-2
89
Ixazomib Approved, Investigational Phase 2 1072833-77-2
90
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
91
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
92
Ichthammol Approved Phase 1, Phase 2 8029-68-3
93
Everolimus Approved Phase 1, Phase 2 159351-69-6 70789204 6442177
94
Acyclovir Approved Phase 2 59277-89-3 2022
95
Clofarabine Approved, Investigational Phase 1, Phase 2 123318-82-1 119182
96
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
97
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
98
Venetoclax Approved, Investigational Phase 2 1257044-40-8 49846579
99
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
100
Sofosbuvir Approved Phase 2 1190307-88-0 45375808
101
Ledipasvir Approved Phase 2 1256388-51-8 67505836
102
Daratumumab Approved Phase 2 945721-28-8
103
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
104
ofatumumab Approved Phase 2 679818-59-8 6918251
105
Levoleucovorin Approved, Investigational Phase 1, Phase 2 68538-85-2
106
Simvastatin Approved Phase 2 79902-63-9 54454
107
Mycophenolic acid Approved Phase 2 24280-93-1 446541
108
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203